Evidence map›Paper›PMID 40320507›Full record

ArticleProbiotics and antimicrobial proteins2026

Characterization and Modeling of Marine Bacillus cereus Strain MSS1 Exopolysaccharide and Its Antagonistic Effect on Colon Cancer.

Sayeda Abdelrazek Abdelhamid, Sahar S Mohamed, Mostafa M Abo Elsoud, Manal S Selim, Marwa M Mounier, Ashraf Eltaher, Sameh Magdeldin, Mohamed Ali, Mohamed E El Awady

Abstract read
In one paragraph

Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sayeda Abdelrazek AbdelhamidMicrobial Biotechnology Department, National Research Centre, Cairo, Egypt. sayeda.abdelrazek@yahoo.com.
Sahar S MohamedMicrobial Biotechnology Department, National Research Centre, Cairo, Egypt.
Mostafa M Abo ElsoudMicrobial Biotechnology Department, National Research Centre, Cairo, Egypt.
Manal S SelimMicrobial Biotechnology Department, National Research Centre, Cairo, Egypt.
Marwa M MounierPharmacognosy Department, National Research Centre, Cairo, Egypt.
Ashraf EltaherProteomics and Metabolomics Research Program, Research Department, Basic Research Unit, Children's Cancer Hospital Egypt 57357, Cairo, 11441, Egypt.
Sameh MagdeldinProteomics and Metabolomics Research Program, Research Department, Basic Research Unit, Children's Cancer Hospital Egypt 57357, Cairo, 11441, Egypt.
Mohamed AliBiochemistry Department, Faculty of Science, Zagazig University, Zagazig, 44519, Egypt.
Mohamed E El AwadyMicrobial Biotechnology Department, National Research Centre, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microbial polysaccharides are a significant group of functional phytochemicals. Numerous studies have shown the advantageous pharmacological impacts of polysaccharides, including their effectiveness against cancer. A halophilic bacterial strain obtained from coastal sediments produced exopolysaccharides (EPS). The strain was morphologically recognized and further confirmed as Bacillus cereus strain MSS1 using 16S rDNA analysis, with accession number OR133726. The heteropolysaccharides were purified and fractionated with a DEAE-cellulose column, and the preliminary chemical analysis of the most potent fraction (EPSMSS1) indicated that the four different monosaccharides were mannuronic acid, xylose, fructose, and glucuronic acid, with a molar ratio of 1:1:2:0.5, respectively. The highest production was 12.76 g/l using a Box-Behnken design. It showed antibacterial activity, antioxidant activity, and antibiofilm activity. The 3D architecture of the EPSMSS1 of Bacillus cereus strain MSS1 is being described, predicted, and aligned against other bacterial species. These studies offer valuable insights into optimizing efficiency. Therefore, the EPSMSS1 fraction was shown to have anticancer activity and significant anticancer activities in a dose-dependent manner, with an IC50 value of 20.1 µg/ml. Subsequently, various apoptotic markers, such as cytochrome c, BAX, BCl2, and the BAX/BCL2 ratio, were assessed. Our findings demonstrate that EPSMSS1 triggers the activation of apoptotic protein BAX, enhances the generation of cytochrome c, reduces the expression of antiapoptotic protein BCl2, and distorts the BAX/BCL2 ratio in EPSMSS1-treated HCT-116 cells relative to untreated cells. The anticancer efficacy of EPSMSS1 was verified through the assessment of cell cycle progression using flow cytometry. It has been found that EPSMSS1 pauses the cell cycle in the G1/S phase, causing apoptosis. The main motivation behind this study was EPSMSS1, an innovative marine polysaccharide with remarkable biological activity, especially anti-cancer properties.

Indexed as

Antineoplastic AgentsBacillus cereusColonic NeoplasmsPolysaccharides, BacterialAnti-Bacterial AgentsApoptosisBiofilmsCell Line, TumorHumansAnti-Bacterial AgentsAntineoplastic AgentsPolysaccharides, BacterialAnti-colon cancerBacillus cereus strain MSS1Exopolysaccharide

Identifiers

PMID40320507
PMCPMC12999837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.